{"id":"W2427633307","doi":"10.1038/ajg.2016.236","title":"The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium","year":2016,"lang":"en","type":"article","venue":"The American Journal of Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":323,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"U.S. National Library of Medicine; National Human Genome Research Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; Crohn's and Colitis Foundation","keywords":"Medicine; Hazard ratio; Vedolizumab; Internal medicine; Discontinuation; Adverse effect; Gastroenterology; Retrospective cohort study; Surgery; Confidence interval; Proportional hazards model; Inflammatory bowel disease; Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008105407,0.0001526583,0.0002925169,0.0000232223,0.0001813063,0.00001409191,0.0004362724,0.00002329455,0.000002509533],"category_scores_gemma":[0.0003425262,0.00006602053,0.0001643196,0.00003128314,0.001323418,0.000007007061,0.000120144,0.00009761505,5.328754e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002772119,"about_ca_system_score_gemma":0.0001309941,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000299553,"about_ca_topic_score_gemma":0.000235335,"domain_scores_codex":[0.9980242,0.0009376385,0.0004550544,0.0001862779,0.0001237579,0.0002730297],"domain_scores_gemma":[0.9976183,0.0006135269,0.0009809735,0.0004555719,0.0002157631,0.000115861],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.68998,0.00009551558,0.2758063,0.00001904425,0.0009734225,0.0000761675,0.0001425418,0.0004477269,0.02416592,0.00017827,0.001665558,0.00644953],"study_design_scores_gemma":[0.003307642,0.001188169,0.9930421,0.00004879523,0.0001208034,0.00003268594,0.00007426336,0.0000205439,0.0005857308,0.0002930083,0.001225027,0.00006124859],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958622,0.0001498436,0.001142007,0.002030696,0.0001636014,0.0002564759,0.0003730866,0.000002654729,0.00001944636],"genre_scores_gemma":[0.9986634,0.0005338513,0.00005696421,0.0004166665,0.0002508315,0.00001667014,0.000006847466,0.00001851008,0.00003623895],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7172358,"threshold_uncertainty_score":0.487619,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005735074284652051,"score_gpt":0.2386958072047946,"score_spread":0.2329607329201426,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}